Magyar onkologia · 2024
[The effect of PSMA PET/CT performed in primary staging on the clinical decision].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Küronya Zsófia, Ágoston Péter, Jorgo Kliton, Gesztesi László, Kapuvári Bence, Dombovári Péter, Mavrogenis Stelios, Géczi Lajos, Lénárt Enikő, Dienes Tamás, Manninger Sándor, Szakáll Szabolcs, Martin Tamás, Biró Krisztina
Аннотация
AIM: Our study aimed to conduct a retrospective statistical analysis of 18F-JK-PSMA-7 PET/CT results in high-risk prostate cancer patients as part of primary staging, to assess how these results influenced the original treatment plan.
METHODS: The study included high-risk prostate adenocarcinoma patients, localized by conventional imaging, who underwent PSMA PET/CT as part of primary staging between 03/01/2020 and 03/01/2022.
RESULTS: PSMA PET/CT confirmed distant metastasis in 20 out of 74 patients. Among them, 7 received local treatment due to oligometastatic disease. The remaining 13 patients had distant lymph node metastasis (1 patient), bone metastasis only (2 patients), or both (10 patients). Based on PSMA PET/CT results, these 13 patients received systemic treatment instead of local therapy. No significant statistical correlation was found between PSA levels, ISUP score, and distant metastasis verification.
CONCLUSION: Broader use of PSMA PET/CT in primary staging of high-risk prostate cancer patients could allow for more precise, personalized therapy in the future.
METHODS: The study included high-risk prostate adenocarcinoma patients, localized by conventional imaging, who underwent PSMA PET/CT as part of primary staging between 03/01/2020 and 03/01/2022.
RESULTS: PSMA PET/CT confirmed distant metastasis in 20 out of 74 patients. Among them, 7 received local treatment due to oligometastatic disease. The remaining 13 patients had distant lymph node metastasis (1 patient), bone metastasis only (2 patients), or both (10 patients). Based on PSMA PET/CT results, these 13 patients received systemic treatment instead of local therapy. No significant statistical correlation was found between PSA levels, ISUP score, and distant metastasis verification.
CONCLUSION: Broader use of PSMA PET/CT in primary staging of high-risk prostate cancer patients could allow for more precise, personalized therapy in the future.
Предметные рубрики MeSH
HumansMalePositron Emission Tomography Computed TomographyProstatic NeoplasmsNeoplasm StagingRetrospective StudiesAgedMiddle AgedClinical Decision-MakingLymphatic MetastasisAdenocarcinomaProstate-Specific AntigenGlutamate Carboxypeptidase IIBone NeoplasmsAged, 80 and overRadiopharmaceuticalsAntigens, Surface